08:35 AM EST, 03/05/2024 (MT Newswires) -- FSD Pharma Inc. ( HUGE ) on Tuesday announced its participation in Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) 2024 Forum held during Feb. 29 - Mar 2, in West Palm Beach, Florida. ACTRIMS, founded in 1995, is comprised exclusively of Multiple Sclerosis (MS) researchers, clinicians and key stakeholders.

FSD shared the results of its Phase-1 clinical study in a poster presentation. This presentation detailed the final results including adverse events (AEs) profile of Lucid-21-302 in the single-ascending dose (SAD) studies. The study concluded that Lucid-21-302 is safe and well-tolerated in the dose range of 50-300 mg p.o. administered once, with no difference in pharmacokinetics between the fed and fasted states. There were no serious adverse events (SAEs), and most AEs (7/12) in participants receiving Lucid-21-302 were characterized as unlikely related or unrelated to study drug. In the dose range 50-300 mg, drug exposure was proportional to dose of the drug. It also demonstrated good oral absorption with AUC at 300mg comparable to AUC in mouse efficacy studies.

Lucid-21-302 is a first-in-class, non-immunomodulatory, neuroprotective compound with a unique mechanism of action for the treatment of MS.